Atlas Trials

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Clinical trial NCT01926028 · COMPLETED

Trial details

NCT number
NCT01926028
Sponsor
NovaDigm Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Vulvovaginal Candidiasis
Start date
2013-07-01
Primary completion
2015-05-01
Enrollment
188

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.